Journals / Meme Sağlığı Dergisi / 2014 / Cilt: 10 - Sayı: 1

Meme kanseri ile ilişkili lenfödem ve tedavisi

Lymphedema after breast cancer and its treatment

Pages
6–14
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review; incidence, risk factors, approaches for protection of this factors, assessment methods and therapy options for LE are have been discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Lymphedema (LE) is a chronic and progressive condition which is an ab- normal retention of protein-rich fluid in the interstitial space because of inadequate lymphatic drainage.
📊
Key Findings & Data:The inci- dence of breast cancer associated LE is reported 6-30%.
💡
Conclusion & Impact:In this review; incidence, risk factors, approaches for protection of this factors, assessment methods and therapy options for LE are have been discussed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Lymphedema (LE) is a chronic and progressive condition which is an ab- normal retention of protein-rich fluid in the interstitial space because of inadequate lymphatic drainage. One of the most important complications of breast surgery is LE that can occur in the arm, hand and trunk. The inci- dence of breast cancer associated LE is reported 6-30%. The most important risk factors of LE are the type of axillary surgery and amount of chemother- apy and/or radiotherapy exposure after surgery. Recent studies showed that sentinel lymph node biopsy replaces axillary lymph node dissection in breast cancer treatment. For diagnosis of LE; clinical properties such as the unilat- eral or asymmetric character of edema, normal skin color, positive Stemmer sign, increased density of edema and extremity pain should be considered. After diagnosis, assessment of the patient includes obtaining information about anamnesis, physical tests, metastasis and risk of deep vein thrombosis. Treatment of the condition can be summarized under the topic of medi- cal treatment, surgery and physiotherapy. Complex Decongestive Therapy (CDT) is accepted as the golden standard for LE treatment. CDT concept consists of four basic components (manual lymph drainage, skin care, com- pression treatment, therapeutic exercise) and two phases. Finally it should not be forgotten and should be learned that LE is a chronic condition that needs lifelong care. In this review; incidence, risk factors, approaches for protection of this factors, assessment methods and therapy options for LE are have been discussed.

Özet

Lenfödem (LÖ), yetersiz lenfatik drenaj sebebiyle proteinden zengin sıvı- nın interstisyel aralıkta anormal birikimi sonucu oluşan kronik ve ilerleyici bir durumdur. Meme kanseri tedavisinin en önemli komplikasyonlarından biri de; kol, el ve gövdede gelişebilecek L֒dür. Meme kanseri ile ilişkili LÖ görülme insidansının %6-30 arasında olduğu belirtilmektedir. L֒nün en önemli risk faktörleri; aksiller cerrahinin tipi ve cerrahi sonrası hastanın aldığı kemoterapi ve/veya radyoterapi miktarıdır. Son yapılan çalışmalar meme kanseri tedavisinde; aksiller lenf nodu diseksiyonunun yerini, senti- nel lenf nodu biopsisinin aldığını ortaya koymuştur. LÖ tanısı konulurken ödemin tek taraflı veya asimetrik olması, cilt renginin normal olması, Stem- mer işaretinin pozitif olması, ödemin yoğunluğunun artmış olması ve eks- tremitenin ağrısız olması gibi klinik özelliklere dikkat edilir. LÖ tanısı ko- nulduktan sonra hastanın değerlendirilmesi öykü, fiziksel testler, metastaz ve derin ven trombozu riskinin sorgulanmasını kapsar. Hastalığın tedavisi ise medikal tedavi, cerrahi tedavi ve fizyoterapi başlıkları altında toplana- bilir. Kompleks Dekonjestif Terapi (KDT) LÖ tedavisi için altın standart olarak kabul edilmektedir. KDT konsepti dört temel bileşen (manuel lenf drenajı, cilt bakımı, kompresyon tedavisi ve terapatik egzersiz) ve iki fazdan oluşmaktadır. Sonuçta unutulmaması ve öğretilmesi gereken L֒nün hayat boyu bakım gerektiren kronik bir rahatsızlık olduğudur. Bu derlemede LÖ gelişimi için; insidans, risk faktörleri, bu faktörlerin önlenmesine yönelik yaklaşımlar, değerlendirme yöntemleri ve tedavi seçenekleri tartışılmaktadır.

🔖

Cite This Article

BAKAR, Y., BERDİCİ, B., ŞAHİN, N., PALA, Ö. O. (2014). Meme kanseri ile ilişkili lenfödem ve tedavisi. Meme Sağlığı Dergisi, Cilt: 10 - Sayı: 1, 6–14. https://ajindex.com/articles/278063

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Chen C, Crooks S, Keely V, Mortimer P, Sitzia J, Todd J. BLS Clinical definition. Sevenoasks: British Lymphology Society 2001. Avaliable from: URL: http:// www.thebls.com/files/60.doc 2. Mortimer PS. Managing lymphedema. Clin Exp Dermatol 1995; 20: 98- 106. (PMID: 8565266) [CrossRef] 3. Erickson VS, Pearson ML, Ganz PA, Adams J, Kahn KL. Arm edema in breast cancer patients. J Natl Cancer Inst 2001; 93:96-111. (PMID: 11208879) [CrossRef] 4. Fu MR, Ridner SH, Hu SH, Stewart BR, Cormier JN, Armer JM. Psychosocial impact of lymphedema: a systematic review of literatu- re from 2004 to 2011. Psychooncology 2013; 22:1466-1484. (PMID: 23044512) [CrossRef] 5. Ayşegül Yıldız, Özgül Karayurt. Meme Kanserli Kadınların Lenfödem Nedeniyle Yaşadıkları Güçlükler. J Breast Health 2011; 7:154-162. 6. Howlader N, Noone A, Krapcho M, Neyman N, Aminou R, Waldron W. SEER cancer statistics review, 1975-2008.
  2. Bethesda, MD: National Cancer Institute, 2011. 7. Petrek JA, Heelan MC. Incidence of breast carcinoma-related lymphede- ma. Cancer 1998; 83:2776-2781. (PMID: 9874397) [CrossRef] 8. Geller BM, Vacek PM, O’Brien P, Secker-Walker RH. Factors associated with arm swelling after breast cancer surgery. J Womens Health (Larchmt) 2003; 12:921-930. (PMID: 14670172) [CrossRef] 9. Norman SA, Localio AR, Potashnik SL, Simoes Torpey HA, Kallan MJ, Weber AL, Miller LT, Demichele A, Solin LJ. Lymphedema in breast can- cer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol 2009; 27:390-397. (PMID: 19064976) [CrossRef] 10. Clark B, Sitzia J, Harlow W. Incidence and risk of arm oedema following treatment for breast cancer: a three-year follow-up study. QJM 2005; 98: 343-348. (PMID: 15820971) [CrossRef] 11. Engel J, Kerr J, Schlesinger-Raab A, Sauer H, Holzel D. Axilla surgery severely affects quality of life: results of a 5-year prospective study in bre- ast cancer patients. Breast Cancer Res Treat 2003; 79:47-57. (PMID: 12779081) [CrossRef] 12. Herd-Smith A, Russo A, Muraca MG, Del Turco MR, Cardona G. Prog- nostic factors for lymphedema after primary treatment of breast carcino- ma. Cancer 2001; 92:1783-1787. (PMID: 11745250) [CrossRef] 13. Paskett ED, Naughton MJ, McCoy TP, Case LD, Abbott JM. The epi- demiology of arm and hand swelling in premenopausal breast cancer sur- vivors. Cancer Epidemiol Biomarkers Prev 2007; 16:775-782. (PMID: 17416770) [CrossRef] 14. Petrek JA, Senie RT, Peters M, Rosen PP. Lymphedema in a cohort of bre- ast carcinoma survivors 20